Imfinzi Plus BCG Improves Disease-Free Survival in High-Risk NMIBC
Lenvima Combo Fails to Extend Survival in Esophageal Cancer
Sevabertinib Effective in Pretreated and First-Line HER2-Mutant NSCLC
Supervised Physical Activity Does Not Improve Quality of Life in Metastatic Cancer